3,4-Dihydroxymethcathinone

3,4-Dihydroxymethcathinone
Clinical data
Other names	HHMC; Dihydroxymethcathinone; 3,4-Dihydroxy-N-methylcathinone; 3,4HO-MC; 3′,4′-Hydroxy-2-(methylamino)propanophenone
Drug class	Norepinephrine–dopamine releasing agent
Identifiers
	IUPAC name 1-(3,4-dihydroxyphenyl)-2-(methylamino)propan-1-one;
CAS Number	22930-83-2;
PubChem CID	13518666;
ChemSpider	27284926;
UNII	RZR1W6RS9C;
Chemical and physical data
Formula	C10H13NO3
Molar mass	195.218 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C(=O)C1=CC(=C(C=C1)O)O)NC;
	InChI InChI=1S/C10H13NO3/c1-6(11-2)10(14)7-3-4-8(12)9(13)5-7/h3-6,11-13H,1-2H3; Key:NIRQIFAAAYJDGZ-UHFFFAOYSA-N;

3,4-Dihydroxymethcathinone (HHMC), or 3,4-dihydroxy-N-methylcathinone, is a monoamine releasing agent of the amphetamine and cathinone families.^[1]^[2] It is an active metabolite of methylone (3,4-methylenedioxymethcathinone; MDMC).^[1]^[2] The drug is a norepinephrine–dopamine releasing agent (NDRA), with EC₅₀Tooltip half-maximal effective concentration values of 110 nM for norepinephrine, 90 nM for dopamine, and 14,100 nM for serotonin in rat brain synaptosomes.^[1]^[2] HHMC was first described in the scientific literature by 2017.^[1]^[2]